<DOC>
	<DOCNO>NCT00537381</DOCNO>
	<brief_summary>The purpose study assess effect intetumumab give combination docetaxel prednisone participant metastatic ( spread cancer cell one part body another ) hormone-refractory ( respond treatment ) prostate cancer ( abnormal tissue grow spread body kill ) .</brief_summary>
	<brief_title>An Efficacy Safety Study Intetumumab ( CNTO 95 ) Participants With Metastatic Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description>This multicenter ( one hospital medical school team work medical research study ) , randomize ( study drug assign chance ) , double-blind ( neither physician participant know treatment participant receives ) study intetumumab combination docetaxel prednisone first-line treatment participant metastatic hormone-refractory prostate cancer . There 2 study group . One group receive intetumumab combination docetaxel prednisone ( study treatment ) group receive placebo ( inactive substance compare drug test whether drug real effect clinical trial ) match intetumumab combination docetaxel prednisone ( control treatment ) . The duration treatment 6 month . Participants respond treatment stable disease well receive extend treatment disease progression ( disease worsen ) additional 6 month , whichever occur first . Treatment continue sponsor 's discretion receive 6 month extend treatment , participant response treatment ( stable disease , partial response , complete response ) . Participants confirm progressive disease receive study treatment may treatment unblinded ( participant know name drug give ) , wish consider alternative treatment . Participants receive control treatment consider complete study treatment , option receive alternative treatment . Alternative treatment either intetumumab along docetaxel prednisone intetumumab alone . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria Confirmed cancer prostate Evidence metastatic disease Have life expectancy great 12 week Have least 4 week previous major surgery date first study agent give Have progressive hormonerefractory disease orchiectomy gonadotropinreleasing hormone analog and/or antiandrogen treatment within 6 month prior first study agent administration Exclusion Criteria Have know Central Nervous System metastases ( cancerous tumor spread brain somewhere else body ) Had prior systemic nonhormonal therapy hormone refractory prostate cancer Have know Human Immunodeficiency Virus ( HIV , lifethreatening infection get infect person 's blood sex infect person ) seropositivity know hepatitis B C infection Have plan major surgery study Have take overthecounter ( medicine buy without prescription ) herbal treatment prostate cancer within 4 week prior first study treatment administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Prostatic neoplasm</keyword>
	<keyword>CNTO 95</keyword>
	<keyword>Intetumumab</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Prednisone</keyword>
</DOC>